Company Profile
Shenzhen YHLO Biotech Co., Ltd.
Founded in 2008, Shenzhen YHLO Biotech Co., Ltd. (YHLO) is a publicly listed company on the Science and Technology Innovation Board (stock code: 688575). Based in Shenzhen, YHLO excels in the research, development, production, sales, and service of in vitro diagnostic (IVD) products. Recognized as a national high-tech enterprise with extensive independent intellectual property rights, YHLO has earned numerous accolades, including being named a National Intellectual Property Demonstration Enterprise and one of Shenzhen's Top 70 Innovative Enterprises.
YHLO utilizes six advanced IVD technology platforms, including chemiluminescence, biochemistry, indirect immunofluorescence, immunoblotting, fluorescent immunochromatography, and colloidal gold immunochromatography. With a portfolio of over 300 products addressing areas such as autoimmunity, reproductive health, infection, liver disease, and respiratory diseases, YHLO’s products are widely implemented across hospitals, community clinics, and third-party testing centers, with a coverage rate exceeding 70 % in China's top-tier hospitals. While firmly rooted in the domestic market, YHLO actively expands its international presence, with products exported to nearly 115 countries and regions, gaining recognition and trust from global customers.
YHLO has made substantial investments in research and development, establishing research centers in Tokyo, Japan; Wuhan, China; and Changsha, China, as well as setting up a production base in Xiangtan, China. As of August 30, 2024, the company has filed for 681 patents, including 58 PCT patents, 367 invention patents, 167 utility model patents, and 22 design patents.
YHLO prioritizes the integration of industry, academia, and research, establishing collaborative laboratories with prestigious institutions such as Peking University, the Institute of Biophysics of the Chinese Academy of Sciences, the Chinese University of Hong Kong (Shenzhen), the Southern University of Science and Technology, the Third People’s Hospital of Shenzhen, Huazhong University of Science and Technology, and the National Innovation Center for High-Performance Medical Devices.
YHLO adheres to the mission of "Focus on healthcare, better life with technology," consistently striving for excellence and delivering outstanding products and services for human health, with the goal of being a leading enterprise in the life sciences and a global leader in in vitro diagnostics.
Milestone
2021
Launched iFlash 1200 the smallest model of iFlash Family
IPO Listed on SSE (Shanghai Stock Exchange)
2020
Launched CLIA Assays for SARS-CoV-2
2019
Launched iModules Modular System
Awarded “Top Innovative Enterprises in Shenzhen”
Won the prize of “Innovation Star Cup for Excellent Reagent”
2018
Awarded “Enterprise with Intellectual Property Advantages”
Launched VISION Pro, the ESR analyzer
Headquarters moved in YHLO Biopark
2017
Launched iFlash 1800 (Bench-top CLIA) and UNICELL POCT System
Awarded “China Most Investment Valuable Brand in IVD Field”
Dr. Frank, YHLO’s chief scientist—— "Lifetime Honorary Award of China IVD Industry Leader”
Inhibin B won the first prize of “Innovative Star Cup”
2016
Launched iFlash 3000, China’s first high throughput CLIA analyzer
Received Europe/US patents for VISION
AMH won the third prize of “Innovative Star Cup”
Corporate Values
Vision
To be a reliable and respected IVD enterprise
Mission
Focus on healthcare, better life with technology
Core Value
Customer focused, Hard working, Innovation, Self-reflective, Quality of work.
Enterprise Spirit
Persistence & Striving for Excellence
Add: Building 1, YHLO Biopark, Baolong 2nd Road, Baolong Subdistrict, Longgang District, 518116 Shenzhen, P.R.China
